Jci_page_head_homepage_01 Jci_page_head_homepage_02
Retroviral integration and human gene therapy
Frederic D. Bushman
Published in Volume 117, Issue 8
J Clin Invest. 2007; 117(8):2083–2086 doi:10.1172/JCI32949
This article Copyright © 2007, The American Society for Clinical Investigation
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 1
Gene correction using retroviral vectors, and monitoring the placement of integration sites after evolution in patients.

A population of cells is removed from the patient (i) and transduced ex vivo with a retroviral vector carrying the corrected gene (ii–iii). The gene-corrected cells are subsequently reinfused into the patient (iv). The population of vector integration sites is diverse prior to transplantation, with each cell harboring integrated proviral copies at different locations in the genome. Examination years later of the population of gene-corrected cells reveals that the population of provirus has changed because of evolution of cells in vivo (v). In some cases this can include proliferation of cells where integrated proviruses activated oncogenes, leading to an adverse event.

Copyright © 2011 American Society for Clinical Investigation.
The JCI is the publication of the ASCI, an honor society of physician-scientists.
Copying, redistribution, and other usage policies